Forecast

The analysts' average price target is €11.90 (+14.98%). The median is €11.90 (+14.98%).

Buy	8
Hold	1
Sell	1

News Go to news feed

Hutchmed share rises 5% after positive phase-III results for lung cancer drug

Hutchmed reported that the Phase-III study SAFFRON for ORPATHYS (Savolitinib) in combination with TAGRISSO (Osimertinib) significantly improved both progression-free survival and overall survival in patients with MET-driven, EGFR-resistant non-small-cell lung cancer. The stock climbed intraday by about 5% to HK$20.14, reaching its highest level since May 11. The global study included 338 patients; the result strengthens the case for worldwide regulatory filings and could extend the combination’s commercial prospects beyond China. » More on de.investing.com
HUTCHMED: China grants conditional approval for gastric cancer drug ORPATHYS, shares jump

China’s drug regulator has granted conditional approval for ORPATHYS (savolitinib) from HUTCHMED for the treatment of MET‑amplified advanced gastric cancer and gastroesophageal junction adenocarcinoma. The approval is based on a Phase II study showing an objective response rate of 32.3% and secondary endpoints including a disease control rate of 63.1% and a median progression‑free survival of 4.0 months. ORPATHYS is the first approval of a selective MET inhibitor for this patient group in China, is being developed jointly with AstraZeneca, and is already listed on the national reimbursement list. After the announcement, HUTCHMED’s shares rose sharply (around +6.5%). » More on de.investing.com
HUTCHMED: ORPATHYS conditionally approved in China for MET‑amplified gastric cancer

China’s drug regulator granted HUTCHMED conditional approval for ORPATHYS (savolitinib) to treat locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with MET amplification after at least two prior systemic therapies. The approval is based on a Phase II study in China showing an objective response rate of 32.3%, a disease control rate of 63.1% and a median progression‑free survival of 4.0 months. ORPATHYS is the first selective MET inhibitor approved in China for this indication; MET amplifications affect about 4–6% of patients (roughly 18,000 cases annually). The drug was co‑developed with AstraZeneca and is already listed on China’s reimbursement list. » More on de.investing.com

Financials

In the last quarter, HUTCHMED (CHINA) LS-,10 Aktie had revenue of €121.92M and net profit of €6.98M

(EUR)	June 2026	YoY
Revenue	121.92M	3.50%
Gross profit	20.74M	55.59%
Net profit	6.98M	96.38%
EBITDA	3.48M	214.94%

Fundamentals

Metric	Value
Market capitalization	€1.8B
Number of shares	174.47M
52-week high/low	€15.79 - €8.43
Dividends	No
Beta	0.43
P/E ratio	130.78
PEG ratio	-1.36
P/B ratio	1.66
P/S ratio	3.83

Company profile

HUTCHMED (China) Limited erforscht, entwickelt und vermarktet gezielte Therapeutika und Immuntherapien für Krebs und immunologische Erkrankungen in Hongkong und international. Das Unternehmen ist in den Segmenten Onkologie/Immunologie und Sonstige Ventures tätig. Das Unternehmen entwickelt Savolitinib, einen Hemmstoff für nicht-kleinzelligen Lungenkrebs (NSCLC), papilläres und Nierenzellkarzinom, kolorektales Karzinom (CRC) und Magenkrebs (GC); und Fruquintinib, einen Hemmstoff für CRC, Brustkrebs, GC, Endometriumkarzinom (EMC), NSCLC, hepatozelluläres Karzinom und gastrointestinale und solide Tumoren. Es entwickelt auch Surufatinib, einen Hemmstoff für neuroendokrine Tumore (NET), pankreatische NET, nicht-pankreatische NET, Gallenwegskrebs, Sarkom, neuroendokrine Neoplasmen, Speiseröhrenkrebs, kleinzelligen Lungenkrebs, GC, Schilddrüsenkrebs, EMC, NSCLC und solide Tumore; HMPL-523, ein Milz-Tyrosinkinase-Hemmer für hämatologische Krebserkrankungen und bestimmte chronische Immunerkrankungen; und HMPL-689 für die Isoform PI3Kd (Phosphoinositid-3'-Kinase delta). Darüber hinaus entwickelt das Unternehmen Tazemetostat, einen Hemmstoff von EZH2 zur Behandlung bestimmter epitheloider Sarkome und follikulärer Lymphome, sowie HMPL-306, einen Hemmstoff für hämatologische Malignome, Gliome und solide Tumore; HMPL-760, ein Bruton-Tyrosinkinase-Inhibitor; HMPL-453, ein Inhibitor für intrahepatische Cholangiokarzinome; HMPL-295 für solide Tumore; HMPL-653 für metastasierende solide Tumore und tenosynoviale Riesenzelltumore; und die Inhibitoren Epitinib (HMPL-813) und Theliatinib (HMPL-309). Das Unternehmen hat Kooperationsvereinbarungen mit AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd, Innovent Biologics Co, Inc. und Genor Biopharma Co. Ltd, Shanghai Junshi Biosciences Co. Ltd. und Epizyme, Inc. Das Unternehmen war früher unter dem Namen Hutchison China MediTech Limited bekannt und änderte im Mai 2021 seinen Namen in HUTCHMED (China) Limited. Das Unternehmen wurde im Jahr 2000 gegründet und hat seinen Hauptsitz in Central, Hongkong.

Name	HUTCHMED (CHINA) LS-,10 Aktie
CEO	Chig Fung Cheng
Headquarters	Hong Kong, Hong Kong
Website	hutch-med.com
Sector	Materials
Industry	Chemicals
IPO	03/16/2016
Employees	1,796